세계의 유전자 치료 출발 물질 시장 : 규모, 점유율, 동향 분석(제품별, 개발 단계별, 용도별, 최종 용도별, 지역별), 부문별 예측(2025-2030년)

Gene Therapy Starting Materials Market Growth & Trends:

The global gene therapy starting materials market size is anticipated to reach USD 5.40 billion by 2030 and is projected to grow at a CAGR of 19.24% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is driven by increasing demand for high-quality raw materials to support the expanding pipeline of gene therapies targeting rare and genetic disorders, cancer, and other complex conditions. As more therapies advance through clinical trials and gain regulatory approvals, the need for scalable, GMP-compliant plasmids, viral vectors, and other key inputs continues to rise.

Furthermore, technological advancements, growing R&D investments, and supportive regulatory frameworks are further accelerating the market. In addition, partnerships between biotech firms and manufacturers are enhancing production capabilities and ensuring a consistent supply chain, positioning the gene therapy starting materials industry for strong and sustained growth through the forecast period.

The COVID-19 pandemic further accelerated the demand for gene therapy starting materials by highlighting the need for rapid therapeutic development and scalable manufacturing. It spurred investments in advanced bioproduction infrastructure and increased focus on genetic platforms, driving growth in plasmid DNA, viral vectors, and other critical components used in both vaccine and gene therapy development.

In addition, the expanding pipeline of gene therapies has further fueled market growth. As more therapies advance into clinical trials and receive regulatory approvals, the demand for high-quality starting materials such as plasmid DNA and viral vectors continues to rise. This has prompted increased investments in manufacturing capacity, advanced technologies, and strategic partnerships, enabling efficient scale-up and supply to meet the evolving needs of gene therapy developers worldwide.

However, strict regulatory requirements for safety, quality, and compliance can delay the development and approval of gene therapy products. While essential for ensuring patient safety, these regulations often involve complex documentation, extensive testing, and prolonged review timelines. This can slow market entry, increase operational costs, and create barriers for smaller companies with limited regulatory expertise. As the industry evolves, navigating these requirements remains a critical challenge for stakeholders in the gene therapy starting materials market.

Gene Therapy Starting Materials Market Report Highlights:

• The viral vectors segment led the market with the largest revenue share of 42.91% in 2024, owing to their high efficiency in gene delivery and widespread use in approved gene therapies. However, the plasmid DNA segment is expected to grow at the fastest CAGR of 20.13% over the forecast period.
• Based on development stage, the clinical therapeutics segment accounted for the largest market share in 2024, driven by the growing number of gene therapy candidates advancing through clinical trials. On the other hand, the pre-clinical therapeutics segment is expected to witness at the fastest CAGR over the forecast period.
• Based on application, the oncology segment accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period, attributed to the rising prevalence of cancer, strong clinical pipeline, and increasing adoption of gene therapies targeting various tumor types. However, the genetic disease segment is projected to grow at a significant CAGR over the forecast period.
• Based on end use, the biopharmaceutical and pharmaceutical companies segment accounted for the largest market revenue share in 2024, driven by increased investment in gene therapy R&D, in-house manufacturing capabilities, and strategic partnerships to accelerate therapy development. On the other hand, the CROs & CMOs segment is expected to register at the fastest CAGR during the projected period.
• North America dominated the market with the largest revenue share in 2024 due to strong R&D investment, advanced manufacturing capabilities, and a high concentration of industry leaders. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Development Stage
  • 1.2.3. Application
  • 1.2.4. End-use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Gene Therapy Starting Materials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Genetic and Rare Diseases
    • 3.2.1.2. Expanding Pipeline of Gene Therapies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Strict Regulatory Requirements
• 3.3. Gene Therapy Starting Materials Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Gene Therapy Starting Materials Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Gene Therapy Starting Materials Market Product Movement Analysis
• 4.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Viral Vectors
  • 4.4.1. Viral Vectors Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.4.2. Adenovirus
    • 4.4.2.1. Adenovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Retrovirus
    • 4.4.3.1. Retrovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Adeno-Associated Virus (AAV)
    • 4.4.4.1. Adeno-Associated Virus (AAV) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Lentivirus
    • 4.4.5.1. Lentivirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 4.5. Plasmid DNA
  • 4.5.1. Plasmid DNA Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 4.6. Cell Lines
  • 4.6.1. Cell Lines Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 5. Gene Therapy Starting Materials Market: Development Stage Estimates & Trend Analysis

• 5.1. Development Stage Segment Dashboard
• 5.2. Global Gene Therapy Starting Materials Market Development Stage Movement Analysis
• 5.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Pre-clinical Therapeutics
  • 5.4.1. Pre-clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.5. Clinical Therapeutics
  • 5.5.1. Clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.6. Marketed Therapeutics
  • 5.6.1. Marketed Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 6. Gene Therapy Starting Materials Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Gene Therapy Starting Materials Market Application Movement Analysis
• 6.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
• 6.5. Infectious Disease
  • 6.5.1. Infectious Disease Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
• 6.6. Genetic Disease
  • 6.6.1. Genetic Disease Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)

Chapter 7. Gene Therapy Starting Materials Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Gene Therapy Starting Materials Market End Use Movement Analysis
• 7.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Biopharmaceutical & Pharmaceutical Companies
  • 7.4.1. Biopharmaceutical & Pharmaceutical Companies Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 7.5. CROs & CMOs
  • 7.5.1. CROs & CMOs Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 7.6. Other
  • 7.6.1. Other Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 8. Gene Therapy Starting Materials Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Company Market Position Analysis, 2024
• 9.3. Strategy Mapping
• 9.4. Participants Overview
  • 9.4.1. Charles River Laboratories
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. GenScript
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Lonza
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Catalent
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Eurofins Scientific
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Danaher
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Merck KGaA
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Revvity, Inc.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Sartorius AG
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives